• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Slovenia Pharmaceuticals and Healthcare Report Q2 2009 - Product Image

Slovenia Pharmaceuticals and Healthcare Report Q2 2009

  • Published: April 2009
  • Region: Slovenia
  • 75 Pages
  • Business Monitor International

FEATURED COMPANIES

  • GlaxoSmithKline
  • Krka
  • Lek (Novartis/Sandoz)
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

The Slovenia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Slovenia's pharmaceuticals and healthcare industry.

In the Business Environment Ranking table adjusted for Q209, Slovenia continued to improve its position in the matrix, rising by one place in relation to the previous period to 11th, out of the 20 main markets surveyed in Central and Eastern Europe (CEE). Despite its small population, Slovenia has one of the most advanced pharmaceutical markets in CEE, mainly due to the relative wealth of the country, a long tradition of pharmaceutical manufacturing and a high level of connection with Western Europe in general. However, Slovenia’s pharmaceutical rating continues to be weighed down by a small market size and low forecast growth, although the high per capita GDP, well-developed healthcare services and widespread health awareness play in favour of pharmaceutical companies. Consequently, the rising demand for novel medicines can be expected to be one of the key drivers of pharmaceutical growth over the forecast period, in combination with an increased focus on private insurance and out-of-pocket spending, given READ MORE >

Executive Summary

SWOT Analysis.

Slovenia Pharmaceuticals And Healthcare Industry SWOT

Slovenia Political SWOT

Slovenia Economic SWOT

Slovenia Business Environment SWOT

Pharmaceutical Business Environment Ratings

Table: Regional Pharma Business Environment Ratings.

Limits Of Potential Returns

Risks To Realisation Of Returns

Market Summary

Regulatory Regime.

Recent EU-Wide Regulatory Developments.

Intellectual Property Regime

IP Deficiencies.

Patent Disputes

Pricing System.

Reimbursement Policies.

Eurozone Entry

Industry Developments

Epidemiology.

Table: Leading Causes Of Death In Slovenia, 2002

Healthcare Sector

Healthcare Provision Developments

Healthcare Insurance

Healthcare Expenditure.

Pharmaceutical Industry

Recent Industry Developments.

Clinical Trials

Medical Devices.

Industry Forecast Scenario

Overall Market Forecast

Table: Slovenia – Drug Expenditure Indicators, Historical Data and Forecasts.

Key Growth Factors – Industry

Table: Slovenia – Health Expenditure Indicators, Historical Data and Forecasts

Macroeconomic Forecast Scenario

Table: Slovenia - Economic Activity

Prescription Market Forecast

Table: Slovenia – Prescription Market Indicators, Historical Data and Forecasts (EURmn unless otherwise stated)

Patented Market Forecast

Table: Slovenia – Patented Drug Market Indicators, Historical Data And Forecasts

Generics Markets Forecast

Table: Slovenia - Generic Drug Market Indicators, Historical Data and Forecasts

OTC Market Forecasts

Table: Slovenia – OTC Market Indicators, Historical Data and Forecasts (EURmn unless otherwise stated)

Table: Slovenia – Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn unless otherwise stated)

Other Healthcare Data Forecasts

Table: Slovenia – Other Health Indicators, Historical Data And Forecasts

Key Risks To BMI’s Forecast Scenario

Competitive Landscape.

Table: Leading Companies In Slovenia. 2007

Company Profiles.

Multinational Company Profiles.

GlaxoSmithKline

Sanofi-Aventis

Pfizer

Novartis

Merck & Co

Indigenous Company Profiles.

Krka.

Lek (Novartis/Sandoz)

Country Snapshot: Slovenia Demographic Data

Section 1: Population.

Table: Demographic Indicators, 2005-2030

Table: Rural/Urban Breakdown, 2005-2030

Section 2: Education And Healthcare

Table: Education, 2002-2005

Table: Vital Statistics, 2005-2030

Section 3: Labour Market And Spending Power

Table: Employment Indicators, 2001-2006

Table: Consumer Expenditure, 2000-2012 (US$)

Table: Average Annual Wages, 2000-2012

BMI Forecast Modelling.

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview.

Table: Pharmaceutical Business Environment Indicators

Weighting.

Table: Weighting Of Components

Sources

- GlaxoSmithKline

- Sanofi-Aventis

- Pfizer

- Novartis

- Merck & Co

- Krka

- Lek (Novartis/Sandoz)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos